Upadacitinib 对比安慰剂或阿达木单抗改善类风湿关节炎患者报告结局:SELECT-COMPARE 研究结果
SELECT-COMPARE 研究在甲氨蝶呤应答不佳的活动性类风湿关节炎患者中,评估 Upadacitinib(15 mg 每日一次)对比安慰剂或阿达木单抗(40 mg 隔周一次)对患者报告结局的影响,随访 48 周。结果显示 Upadacitinib 和 阿达木单抗在第 12 周均优于安慰剂,且 Upadacitinib 在部分患者报告结局上优于阿达木单抗,并维持至 48 周。
要点
- Upadacitinib 和 阿达木单抗在第 12 周所有患者报告结局均优于安慰剂(P < 0.05)。
- 第 12 周 Upadacitinib 在 PtGA、疼痛、HAQ-DI、晨僵严重度、FACIT-F 和 SF-36 PCS 上优于阿达木单抗(P < 0.05)。
- Upadacitinib 组在 HAQ-DI 和 SF-36 PCS 达到规范值的患者比例高于阿达木单抗组(P < 0.05)。
核心结论
- 在甲氨蝶呤应答不佳的类风湿关节炎患者中,Upadacitinib 对患者报告结局的改善具有统计学和临床意义,相当于或优于阿达木单抗。
研究设计与样本
- SELECT-COMPARE 研究(NCT02629159)评估 Upadacitinib 15 mg 每日一次、安慰剂或阿达木单抗 40 mg 隔周一次联合背景甲氨蝶呤治疗 48 周的患者报告结局。
主要发现
- 第 12 周 Upadacitinib 和 阿达木单抗在所有患者报告结局的基线最小二乘均值变化均优于安慰剂(P < 0.05),第 2 周疼痛和晨僵严重度亦优于安慰剂(P < 0.05)。
- 第 12 周 Upadacitinib 组报告所有患者报告结局改善≥最小临床重要差异的患者比例高于安慰剂组(P < 0.05),与阿达木单抗组相似。
- 第 12 周 Upadacitinib 在 PtGA、疼痛、HAQ-DI、晨僵严重度、FACIT-F 和 SF-36 PCS 的基线最小二乘均值变化优于阿达木单抗(P < 0.05)。
- 第 12 周 Upadacitinib 组 HAQ-DI 和 SF-36 PCS 达到规范值的患者比例高于阿达木单抗组(P < 0.05)。
- Upadacitinib 组在 PtGA、疼痛、HAQ-DI、FACIT-F 和晨僵方面维持临床有意义改善至 48 周的患者比例高于阿达木单抗组。
临床怎么用
- 对于甲氨蝶呤应答不佳的活动性类风湿关节炎患者,Upadacitinib 可考虑用于改善患者报告结局,包括疼痛、功能、疲劳和晨僵。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the impact of upadacitinib vs placebo and adalimumab treatment, on patient-reported outcomes (PROs) in SELECT-COMPARE in an active RA population with inadequate responses to MTX (MTX-IR). METHODS: PROs in patients receiving upadacitinib (15 mg QD), placebo, or adalimumab (40 mg EOW) while on background MTX were evaluated over 48 weeks. PROs included Patient Global Assessment of Disease Activity (PtGA) and pain by visual analogue scale (VAS), the HAQ Disability Index (HAQ-DI), the 36-Item Short Form Survey (SF-36), morning (AM) stiffness duration and severity, the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), and work instability. Least squares mean (LSM) changes and proportions of patients reporting improvements ≥ minimal clinically important differences (MCIDs) and scores ≥ normative values were evaluated. RESULTS: Upadacitinib and adalimumab resulted in greater LSM changes from baseline vs placebo across all PROs (P < 0.05) at week 12, and pain and AM stiffness severity (P < 0.05) at week 2. More upadacitinib- vs placebo-treated (P < 0.05) and similar percentages of upadacitinib- vs adalimumab-treated patients reported improvements ≥ MCID across all PROs at week 12. Upadacitinib vs adalimumab resulted in greater LSM changes from baseline in PtGA, pain, HAQ-DI, stiffness severity, FACIT-F, and the SF-36 Physical Component Summary (PCS) (all P < 0.05) at week 12. More upadacitinib- vs adalimumab-treated patients reported scores ≥ normative values in HAQ-DI and SF-36 PCS (P < 0.05) at week 12. More upadacitinib- vs adalimumab-treated patients maintained clinically meaningful improvements in PtGA, pain, HAQ-DI, FACIT-F, and AM stiffness through 48 weeks. CONCLUSION: In MTX-IR patients with RA, treatment with upadacitinib resulted in statistically significant and clinically meaningful improvements in PROs equivalent to or greater than with adalimumab. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT02629159.
引用
- Strand V, Tundia N, Bergman M, et al. Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE. Rheumatology (Oxford). 2021. PMID: 33590829. doi:10.1093/rheumatology/keab158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。